Edwards Lifesciences Corporation Company Profile (NYSE:EW)

Edwards Lifesciences Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences Corporation's stock split before market open on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly issued shares were issued to shareholders after the market closes on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences Corporation stock prior to the split would have 200 shares after the split.

Edwards Lifesciences Corporation (NYSE:EW) released its earnings results on Wednesday, July, 26th. The company reported $1.08 EPS for the quarter, beating the Zacks' consensus estimate of $0.88 by $0.20. The business earned $842 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. Edwards Lifesciences Corporation's quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.76 earnings per share. View Edwards Lifesciences Corporation's Earnings History.

Edwards Lifesciences Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Edwards Lifesciences Corporation.

Edwards Lifesciences Corporation issued an update on its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $3.65-3.85 for the period, compared to the Thomson Reuters consensus estimate of $3.54. The company issued revenue guidance of $, compared to the consensus revenue estimate of $3.35 billion.Edwards Lifesciences Corporation also updated its Q3 guidance to $0.80-0.90 EPS.

20 brokers have issued 12 month price targets for Edwards Lifesciences Corporation's stock. Their forecasts range from $14.00 to $155.00. On average, they anticipate Edwards Lifesciences Corporation's stock price to reach $120.05 in the next year. View Analyst Ratings for Edwards Lifesciences Corporation.

Here are some recent quotes from research analysts about Edwards Lifesciences Corporation stock:

• 1. According to Zacks Investment Research, "Over the last three months, Edwards Lifesciences has outperformed the Zacks categorized Medical - Instruments industry. We believe several recent FDA approvals received by the company including its SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve have been boosting the investors’ confidence over the stock. Also, Edwards Lifesciences’ long-term growth strategy buoys optimism. The company’s focus on bulding its pipeline to strengthen its foothold across all its operating businesses is also encouraging. However, higher operating expenses continue to be a woe. The stock’s valuation also remains stretched on huge investments in the launch and promotion of products. Stiff competition, currency headwind and reimbursement issues are other challenges." (7/18/2017)
• 2. Cowen and Company analysts commented, "After hosting meetings with management last week, attending ACC, and reviewing early 1Q'17 MedMine hospital purchasing data, we remain bullish on Edwards' long term growth prospects. We are optimistic that additional layers of growth will be provided by low risk, asymptomatic and moderate AS indications along with EW's mitral and tricuspid platforms. Reiterate Outperform." (3/28/2017)

Some companies that are related to Edwards Lifesciences Corporation include Boston Scientific Corporation (BSX), Koninklijke Philips N.V. (PHG), Intuitive Surgical (ISRG), Illumina (ILMN), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL), Accelerate Diagnostics (AXDX), Mazor Robotics (MZOR) and Natus Medical Incorporated (BABY).

Edwards Lifesciences Corporation's management team includes the folowing people:

• Michael A. Mussallem, Chairman of the Board, Chief Executive Officer
• Scott B. Ullem, Chief Financial Officer, Corporate Vice President
• Donald E. Bobo Jr., Corporate Vice President - Heart Valve Therapy
• Catherine M. Szyman, Corporate Vice President- Critical Care
• Patrick Bruno Verguet, Corporate Vice President- Europe, Middle East and Africa
• Huimin Wang M.D., Corporate Vice President- Japan, Asia and Pacific
• Larry L. Wood, Corporate Vice President - Transcatheter Heart Valve Therapy
• Bernard J. Zovighian, Corporate Vice President -Surgical Heart Valve Therapy
• Kieran T. Gallahue, Independent Director
• Leslie Stone Heisz, Independent Director

Edwards Lifesciences Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.83%), BlackRock Inc. (6.68%), State Street Corp (4.31%), Alliancebernstein L.P. (2.82%), Bank of New York Mellon Corp (2.52%) and Ameriprise Financial Inc. (2.06%). Company insiders that own Edwards Lifesciences Corporation stock include Barbara J Mcneil, Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Nick Demare, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von and Steven R Loranger. View Institutional Ownership Trends for Edwards Lifesciences Corporation.

Edwards Lifesciences Corporation's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., FMR LLC, Fred Alger Management Inc., Voya Investment Management LLC, Marshall Wace North America L.P., Winslow Capital Management LLC, Alliancebernstein L.P. and State Street Corp. Company insiders that have sold Edwards Lifesciences Corporation stock in the last year include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo, Jr, Huimin Wang, Larry L Wood, Michael A Mussallem and Patrick B Verguet. View Insider Buying and Selling for Edwards Lifesciences Corporation.

Edwards Lifesciences Corporation's stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Egerton Capital UK LLP, Koch Industries Inc., Artisan Partners Limited Partnership, Harbour Capital Advisors LLC, Vanguard Group Inc., Wells Fargo & Company MN and Delta Lloyd Asset Management N.V.. Company insiders that have bought Edwards Lifesciences Corporation stock in the last two years include Catherine M Szyman, Dylan Sidoo, Kieran Gallahue, Nick Demare and Steven R Loranger. View Insider Buying and Selling for Edwards Lifesciences Corporation.

Shares of Edwards Lifesciences Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Edwards Lifesciences Corporation stock can currently be purchased for approximately $110.64.